Received Jan 30, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 1 | — | — |
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 2 | — | — |
patient received their 2nd dose of RECOMBIVAX HB early, at 25 days after the first when she was an infant, and has not yet received the 3rd dose.; No additional AE; This spontaneous report was received from a medical assistant and refers to a 13-year-old female patient. The patient's concurrent conditions, medical history, previous drug reactions, drug allergies and concomitant therapies were not reported. On an unspecified date (When she was an infant), the patient was vaccinated with the first two doses of Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB) with a separation of 25 days in between (strength, frequency, route of administration, site of administration, lot #, and expiration date were not provided) as prophylaxis. At the reporting time, the patient had not yet received the 3rd dose (Inappropriate schedule of product administration). No adverse effects were reported.